ORIGINAL PAPER
The status of the C3 and C4 fractions of the complement system in children with Henoch-Schönlein purpura
 
More details
Hide details
1
2nd Department of Pediatrics, Kharkiv National Medical University, Kharkiv, Ukraine
 
 
Submission date: 2019-04-03
 
 
Final revision date: 2019-06-28
 
 
Acceptance date: 2019-07-13
 
 
Publication date: 2019-08-30
 
 
Pediatr Pol 2019;94(4):229-234
 
KEYWORDS
TOPICS
ABSTRACT
Aim of the study:
To determine the interaction of components of complement C3 and C4 with indicators of unspecific immune system and biological inflammatory markers.

Material and methods:
A total of 80 children were recruited, including 60 patients with Henoch-Schönlein purpura (HSP) aged from 2 to 17 years old and 20 healthy children of the same age. The HSP patients were divided into two groups: an HSPWN group (n = 47), including HSP patients without renal involvement; and an HSPN group (n = 13), including patients with HSP combined with renal syndrome. The control group comprised 20 healthy children. Standard tests, clinical examination, and measurement of the levels of C3 and C4 complement fractions were performed on admission and during remission time. The components of the complement system C3 and C4 were determined by ELISA using standard ELISA C3 and C4 kits from AssayPro, USA.

Results:
It was significantly proved the difference between medians in all groups due to high criteria H for C3 in acute and remission periods (H = 15.58, p = 0.000 and H = 14.58, p = 0.00, respectively). The serum level of C3 was significantly decreased in patients of HSPWN and HSPN groups in the acute period (pHSPWN-C = 0.000, pHSPN-C = 0.004) and during remission (pHSPWN-C = 0.000, pHSPN-C = 0.018), compared with controls. The serum level of C4 was significantly decreased in patients in the HSPWN group in the acute period compared with patients on the HSPN group (pHSPWN-HSPN = 0.020). The level of C4 was significantly lower during remission time in both groups (T = 144.0, p = 0.041 and T = 10.5, p = 0.025, respectively).

Conclusions:
Abnormalities of the complement system in HSP have been reported. Hypocomplementaemia was not dependent on the severity of the process of HSP. In the period of remission, the levels of C3 and C4 approached the control group’s values.
REFERENCES (24)
1.
Kraft DM, Mckee D, Scott C. Henoch-Schönlein purpura: a review. Am Fam Physician 1998; 58: 405-408, 411.
 
2.
Hung SP, Yang YH, Lin YT, et al. Clinical manifestations and outcomes of Henoch-Schönlein purpura: comparison between adults and children. Pediatr Neonatol 2009; 50: 162-168.
 
3.
Hong J, Yang HR. Laboratory Markers Indicating Gastrointestinal Involvement of Henoch-Schönlein Purpura in Children. Pediatr Gastroenterol Hepatol Nutr 2015; 18: 39-47.
 
4.
Pillebout E, Jamin A, Ayari H, et al. Biomarkers of IgA vasculitis nephritis in children. PLoS One 2017; 12: e0188718.
 
5.
Sun L, Xie B, Zhang Q, et al. Biomarkers identification by a combined clinical and metabonomics analysis in Henoch-Schonlein purpura nephritis children. Oncotarget 2017; 8: 114239-114250.
 
6.
Purevdorj N, Mu Y, Gu Y, et al. Clinical significance of the serum biomarker index detection in children with Henoch-Schonlein purpura. Clin Biochem 2018; 52: 167-170.
 
7.
Welch TR. The complement system in renal diseases. Nephron 2001; 88: 199-204.
 
8.
Yang YH, Tsai IJ, Chang CJ, et al. The interaction between circulating complement proteins and cutaneous microvascular endothelial cells in the development of childhood Henoch-Schönlein purpura. PloS One 2015; 10: e0120411.
 
9.
Ozen S, Pistorio A, Iusan SM, et al. Criteria for Henoch-Schonlein purpura, childhood polyarteritisnodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2019; 69: 798-806.
 
12.
Davin JC, Coppo R. Henoch-Schönlein purpura nephritis in children. Nat Rev Nephrol 2014; 10: 563-573.
 
13.
Saulsbury FT. Review Henoch-Schönlein purpura. Curr Opin Rheumatol 2010; 22: 598-602.
 
14.
Chan H, Tang YL, Lv XH, et al. Risk factors associated with renal involvement in childhood Henoch-Schönlein Purpura: A Meta-Analysis. PLoS One 2016; 11: e0167346.
 
15.
Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99: 1053-1059.
 
16.
Brendel-Müller K, Hahn A, Schneppenheim R, Santer R. Laboratory signs of activated coagulation are common in Henoch-Schönlein purpura. Pediatr Nephrol 2001; 16: 1084-1088.
 
17.
Jung DY, Kwon YR, Yu MH, et al. Clinical Features and Prognosis of Henoch-Schönlein Purpura in Children and Adults: A 13-Year Retrospective Study at a Single Centre. Child Kidney Dis 2017; 21: 61-68.
 
18.
Saulsbury FT. Henoch-Schonlein Purpura in Children: Report of 100 Patients and Review of the Literature. Medicine 1999; 78: 395-409.
 
19.
Yang HR. What We Know about Henoch-Schönlein Purpura in Children up to Date? Korean Med Sci 2018; 33: e199.
 
20.
Smith GC, Davidson JE, Hughes DA, et al. Complement activation in Henoch-Schönlein purpura. Pediatr Nephrol 1997; 11: 477-480.
 
21.
Lin Q, Min Y, Li Y, et al. Henoch-Schönlein purpura with hypocomplementemia. Pediatr Nephrol 2012; 27: 801-806.
 
22.
Motoyama O, Iitaka K. Henoch-Schonlein purpura with hypocomplementemia in children. Pediatr Int 2005; 47: 39-42.
 
23.
Levi M. Two-way interactions between inflammation and coagulation. Cardiovasc Med 2005; 15: 254-259.
 
24.
Dolezalova P, Telekesova P, Nemkova D, Hoza J. Incidence of vasculitis in children in the Czech republic: 2-year prospective epidemiology survey. J Rheumatol 2004; 31: 2295-2299.
 
Journals System - logo
Scroll to top